Ocular inflammatory changes have been a recognised occurrence in multiple sclerosis (MS) for many years, ' although their pathogenetic significance remain uncertain. Recent studies have found associations between retinal vascular abnormalities and both the later development of MS in patients presenting with isolated optic neuritis (ON)2 and neurological disease activity in patients with established MS. 3 In this study we have sought the prevalence of ocular inflammatory changes (uveitis) in patients with clinically definite MS and correlated their presence with clinical course and disease severity. Our findings may shed further light on their occurrence and pathogenesis.
Patients and methods
We studied consecutive patients with clinically definite MS but without preceding ocular disease (see below),4 who were admitted to one neurological firm at the National Hospital, Queen Square, London. Patients with a past history ofocular disease, other than optic neuritis, or systemic illness associated with ocular abnormalities were excluded. A total of 50 patients was collected, 27 were female and 23 male. Their mean age at presentation of first neurological symptoms was 28-3 years (range 16-51 years).
Patients were categorised according to the severity (mild, moderate or severe) and clinical course (remittent or currently progressive) of their disease. Patients with mild disease had a score of < 3 on the Kurtzke disability scale,5 moderate disease 3 5-6 and severe disease > 6 at the time ofassessment.
Patients with currently progressive MS had shown either a progressive evolution of disease from onset or had entered a progressive phase following initial remissions.
All fifty patients had a full ophthalmological examination. This included assessment ofcorrected visual acuity (Snellen), colour vision (Ishihara plates), visual fields (Bjerrum screen); slit-lamp examination and direct and indirect ophthalmoscopy. Fluorescein angiography was performed only when clinically indicated. Ocular inflammation (uveitis) was defined by the presence of inflammatory cells in the vitreous with either sheathing ofperipheral retinal vessels and/or focal cuffing of retinal veins (periphlebitis).
Results

Neurologicalfeatures
The neurological features are summarised in table 1. The mean duration of MS for the group as a whole was 12-3 years (range 0-5-38 years); fifty per cent of patients had had neurological symptoms for 10 years or more. Thirty four patients (68%) had remittent disease and in 16 patients (32%) the disease was currently progressive. The age at onset and disease This study is confined to the first group of patients defined above in which we have found an 18% prevalence of ocular vascular abnormalities, consistent with uveitis, in patients with established MS. This figure is comparable to other hospital based series3"' but contrasts with recorded prevalences of only 1%-5% noted among patients with quiescent MS attending rehabilitation centres.3 However, all nine patients in our study with ocular changes had active neurological disease; this concords with the studies of Bamford et al" and Engell3 in which 20-40% of patients with a severe or progressive course had coexistent uveitis. Together these findings support the concept that ocular inflammatory changes may represent the visible correlate of concomitant active CNS demyelination. There are histological and antigenic similarities between retinal and cerebral vascular endothelium which may be important in the early stages of demyelination. These similarities are discussed fully elsewhere. 2 12 One question which remains unanswered is why not all patients with active MS show similar retinal changes. It is possible that asymptomatic retinal vascular inflammation is a transient phenomenon occurring only at the onset of an acute neurological relapse and therefore missed by the unsuspecting physician. In addition, in many cases the inflammatory changes are in the most peripheral vessels and only seen with the indirect ophthalmoscope. We would like to propose a third explanation. One patient in our series showed signs of florid ocular inflammation in one eye only, the other eye, with pronounced optic atrophy following previous trauma, was unaffected. We also noted that uveitis was clinically more pronounced in those eyes unaffected by optic atrophy. It is generally accepted that severe optic atrophy appears to "protect" against ocular inflammation.
Graham, Francis, Sanders, Rudge For example patients with Behcet's disease who experience recurrent uveitis with retinal vascular occlusion will eventually develop optic atrophy; at this stage the ocular disease process is arrested and uveitis never recurs (EMG unpublished data).
The mechanism of this phenomenon is unclear but there are at least two possible explanations. One is to assume that severe optic atrophy reduces retinal vascularity and lessens the opportunity for immunological reactions to take place at the vascular endothelium. The second is that, if a component of CNS tissue is the prime immunological target, the inflammatory reaction would be expected to subside with its progressive loss. The electrodiagnostic and fluorescein studies in our patient with traumatic left optic atrophy confirmed that optic nerve damage was the predominant pathological feature in the left eye whereas retinal damage was more pronounced in the right eye. Retinal photoreceptor damage is known to occur as a result of retinal vasculitis'3 and this is borne out by the asymmetrical ERG responses we obtained; the ERG from the "unaffected" left eye indicated almost intact photoreceptor function. These findings would therefore seem to support the former explanation that the development of ocular inflammation requires an adequate blood supply. The retinal perivascular abnormalities seen in patients with MS may thus represent a visible manifestation of active inflammation occurring within the CNS but which is potentially masked by optic atrophy occurring secondary to clinical or subclinical optic neuritis. Other investigators have noted a negative correlation between "retinal sheathing" and optic atrophy in MS' but our observations require more detailed confirmation before firm conclusions can be made.
